Evidence map›Paper›PMID 42098382›Full record

GuidelineBone marrow transplantation2026

Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committee.

Roser Velasco, Martin Schmidt-Hieber, Olaf Penack, Dina Averbuch, Aitana Balaguer-Roselló, Francesco Baccelli, Luis Bataller, Simone Cesaro, Chiara Briani, Rafael de la Cámara and 17 more

Abstract readPractice GuidelineReview
PubMed Publisher
In one paragraph

Guideline in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Roser Velasco *Department of Neurology, Neuro-oncology Unit, Institut Català d'Oncologia - Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. rvelascof@bellvitgehospital.cat.ORCID 0000-0003-3194-9406
Martin Schmidt-Hieber *Clinic for Oncology, Hematology, Pneumology, Nephrology and Diabetology, Medical University Lausitz - Carl Thiem (MUL-CT), Cottbus, Germany.ORCID 0000-0002-3071-6945
Olaf PenackComplications Working Party, EBMT, Paris, France.ORCID 0000-0003-4876-802X
Dina AverbuchInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0001-9614-7274
Aitana Balaguer-RosellóDepartment of Hematology, Hospital Universitari I Politècnic la Fe, València, Spain.ORCID 0000-0003-1633-2918
Francesco BaccelliInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0003-2242-3998
Luis BatallerDepartment of Neurology, Instituto Valenciano de Oncología, Valencia, Spain.ORCID 0000-0002-2471-4492
Simone CesaroInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0002-8698-9547
Chiara BrianiDepartment of Neurosciences, Neurology Unit, University of Padova, Padova, Italy.ORCID 0000-0001-8035-0200
Rafael de la CámaraInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0002-8189-5779
Petra HuehnchenCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department for Neurology with Experimental Neurology, Berlin, Germany.ORCID 0000-0002-6825-7270
Thushan de SilvaInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0002-6498-9212
Alberto MussettiComplications Working Party, EBMT, Paris, France.ORCID 0000-0002-4088-036X
Per LjungmanInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0002-8281-3245
Zinaida PerićComplications Working Party, EBMT, Paris, France.ORCID 0000-0001-9458-8025
Malgorzata MikulskaInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0002-5535-4602
Alexey PolushinR.M. Gorbacheva Research Institute, Pavlov University, St, Petersburg, Russia.ORCID 0000-0001-8699-2482
David Navarro OrtegaInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0003-3010-4110
Albert Pons-EscodaBellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0003-4167-8291
Dionysios NeofytosInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0001-6970-2869
Hélène SchoemansComplications Working Party, EBMT, Paris, France.ORCID 0000-0002-7568-8239
José Luis PiñanaInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0001-8533-2562
Francesco OnidaPractice Harmonisation and Guidelines Committee, EBMT, Barcelona, Spain.ORCID 0000-0002-2991-3474
Annalisa RuggeriPractice Harmonisation and Guidelines Committee, EBMT, Barcelona, Spain.ORCID 0000-0002-7261-2765
Isabel Sanchez-OrtegaPractice Harmonisation and Guidelines Committee, EBMT, Barcelona, Spain.ORCID 0009-0005-5519-9154
Ibrahim Yakoub-AghaPractice Harmonisation and Guidelines Committee, EBMT, Barcelona, Spain.ORCID 0000-0003-4524-8782
Jan StyczynskiInfectious Diseases Working Party, EBMT, Leiden, Netherlands.ORCID 0000-0002-3158-119X

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) PE 1450/7-1, PE 1450/9-1, PE 1450/10-1, PE 1450/11-1Deutsche Krebshilfe (German Cancer Aid) 70113519Generalitat de Catalunya (Government of Catalonia) SLT042/25/000013Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) JR24/00028Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI24/01279
6 · The paper itself

Abstract

Central nervous system complications (CNSC) after allogeneic hematopoietic cell transplantation (allo-HCT) are relatively common and may have a major impact on patients´ outcomes. Neurological symptoms may occur at any point during the post-transplant course, although they are more common early after HCT, with a wide range of possible presentations. As many of CNSC symptoms are non-specific, the initial assessment is often difficult, and early decisions regarding the diagnostic work-up can influence the identification of the underlying cause. Blood tests, neuroimaging and cerebrospinal fluid (CSF) analyses are particularly important, as they frequently provide the first clues that help narrow the very wide differential diagnoses. In view of these challenges, an international EBMT working group composed of haematologists, infectious disease specialists, neurologists, a neuroradiologist, and a microbiologist developed symptom-based recommendations for the early evaluation of CNSC after allo-HCT. The work summarizes key aspects of the clinical presentation and outlines practical steps for the initial diagnostic approach. These recommendations are intended to support haematologists, who are usually the first to assess these patients, in promptly recognizing CNSC so to start timely appropriate management.

Indexed as

Central Nervous System DiseasesHematopoietic Stem Cell TransplantationHumansTransplantation, Homologous

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.